Home|Journals|Articles by Year|Audio Abstracts
 

Original Research

RMJ. 2013; 38(2): 131-133


Comparison between 1%permethrin, Trimethoprim-sulfamethoxazole and Crotamiton in the treatment of Pediculosis capitis

Basel Alrawashdeh, Taghreed J Almaaita.




Abstract

Objective: to compare the efficacy of three different treatments for pediculosis capitis.
Materials and methods: a prospective study was carried out at Jordanian military field hospital in Gaza from August 2012 to October 2012.A total number of sixty patients were included in this study.Pediculosis capitis was diagnosed by direct examination of scalp and hair. The diagnosis was confirmed by direct light microscopic examination.
Patients were divided into three equal groups:
The first group received 1% permethrin cream, the second group received only oral Trimethoprim-sulfamethoxazole and the third group received crotamiton lotion.
To assess cure rate we followed these patients up to two and four weeks after completing their treatment. Absence of adults’ lice and nits was considered a cure.
Result: The group who received 1% permethrin cream showed the highest cure rate, while those who received oral Trimethoprim-sulfamethoxazole showed the lowest cure rate.
Conclusion: 1 % permethrin cream rinse was the best treatment to head lice to date, but oral TM-SMX therapy is not recommended.

Key words: Permethrin, crotamiton, pediculosis capitis






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.